Evidence map›Paper›PMID 33079221›Full record

ReviewAnnals of hematology2021

Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Maximilian Christopeit, Martin Schmidt-Hieber, Rosanne Sprute, Dieter Buchheidt, Marcus Hentrich, Meinolf Karthaus, Olaf Penack, Markus Ruhnke, Florian Weissinger, Oliver A Cornely and 1 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. SEOM-GGCC clinical guidelines for the prophylaxis of infectious diseases in patients with cancer (UPDATE 2026).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  8. Antifungal Management in Patients with Hematological Malignancies: From Primary Prophylaxis to Empirical and Diagnosis-Driven TreatmentTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026
    Review
  9. Review
  10. Review
  11. Preoperative cardiovascular evaluation in patients with cancer.Frontiers in cardiovascular medicine · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Cholestasis in hepatitis E virus infection.World journal of hepatology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 2 countries.

Maximilian Christopeit *Department of Stem Cell Transplantation, University Medical Center Eppendorf, Hamburg, Germany. Maximilian.Christopeit@med.uni-tuebingen.de.ORCID http://orcid.org/0000-0003-4627-0412
Martin Schmidt-Hieber *Department of Hematology and Oncology, Carl-Thiem-Klinikum, Cottbus, Cottbus, Germany.
Rosanne Sprute *Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Dieter BuchheidtDepartment of Hematology and Oncology, Mannheim University Hospital, Heidelberg University, Mannheim, Germany.
Marcus HentrichDepartment of Medicine III-Hematology/Oncology, Red Cross Hospital, Munich, Germany.
Meinolf KarthausDepartment of Internal Medicine, Hematology and Oncology, Klinikum Neuperlach, Städtisches Klinikum München, Munich, Germany.
Olaf PenackDepartment of Internal Medicine, Division of Hematology and Oncology, Charité Universitätsmedizin Berlin, Campus Rudolf Virchow, Berlin, Germany.
Markus RuhnkeDepartment of Hematology, Oncology and Palliative Medicine, Helios Hospital Aue, Aue, Germany.
Florian WeissingerDepartment of Internal Medicine, Hematology, Oncology, Stem Cell Transplantation and Palliative Medicine, Protestant Hospital of Bethel Foundation, Bielefeld, Germany.
Oliver A Cornely *Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Georg Maschmeyer *Klinikum Ernst von Bergmann, Department of Hematology, Oncology and Palliative Care, Potsdam, Germany.
University of Cologne · DECarl-Thiem-Klinikum Cottbus · DECharité - Universitätsmedizin Berlin · DEEvangelisches Krankenhaus Bielefeld · DEGerman Red Cross · DEHeidelberg University · DEKlinikum Ernst von Bergmann · DEMünchen Klinik · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To ensure the safety of high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT), evidence-based recommendations on infectious complications after HDC/ASCT are given. This guideline not only focuses on patients with haematological malignancies but also addresses the specifics of HDC/ASCT patients with solid tumours or autoimmune disorders. In addition to HBV and HCV, HEV screening is nowadays mandatory prior to ASCT. For patients with HBs antigen and/or anti-HBc antibody positivity, HBV nucleic acid testing is strongly recommended for 6 months after HDC/ASCT or for the duration of a respective maintenance therapy. Prevention of VZV reactivation by vaccination is strongly recommended. Cotrimoxazole for the prevention of Pneumocystis jirovecii is supported. Invasive fungal diseases are less frequent after HDC/ASCT, therefore, primary systemic antifungal prophylaxis is not recommended. Data do not support a benefit of protective room ventilation e.g. HEPA filtration. Thus, AGIHO only supports this technique with marginal strength. Fluoroquinolone prophylaxis is recommended to prevent bacterial infections, although a survival advantage has not been demonstrated.

Indexed as

Hematopoietic Stem Cell TransplantationGermanyHematologic NeoplasmsHematologyHepacivirusHepatitis BHepatitis B AntibodiesHepatitis B virusHepatitis CHumansMedical OncologyPneumocystis cariniiPneumonia, PneumocystisPractice Guidelines as TopicRNA, ViralSocieties, MedicalHepatitis B AntibodiesRNA, ViralTrimethoprim, Sulfamethoxazole Drug CombinationAutologous stem cell transplantationInfection

Identifiers

PMID33079221
PMCPMC7572248
OpenAlexW3093380568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.